CytomX Therapeutics: Doubling Overnight On Phase 1 Data
CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a $100 million stock offering, extending cash runway through 2025. CX-904 development with Amgen discontinued, but collaboration continues on a preclinical T-cell engager project.
CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden - CFO Wayne Chu - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Anupam Rama - JPMorgan Peter Lawson - Barclays Robert Driscoll - Wedbush Securities Daniel Smith - H.C. Wainwright Operator Good morning, everyone, and thank you for standing by.
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.17 per share a year ago.
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to earnings of $0.01 per share a year ago.
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants Roger Song - Jefferies Joe Catanzaro - Piper Sandler Anupam Rama - JPMorgan Peter Lawson - Barclays Operator Good afternoon, everyone. Thank you for standing by.
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?
On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
CytomX Therapeutics (CTMX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Chris Ogden - CFO Sean A. McCarthy - Chairman and CEO Conference Call Participants Joseph Catanzaro - Piper Sandler Liang Cheng - Jefferies Etzer Darout - BMO Capital Markets Anupam Rama - J.P.
